Loading…
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is currently undergoing clinical evaluation as an antivascular agent for the treatment of cancer. We have previously demonstrated that DMXAA induces apoptosis of vascular endothelial cells in murine tumour sections and in a breast carcinoma biopsy from on...
Saved in:
Published in: | British journal of cancer 2004-02, Vol.90 (4), p.906-910 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783 |
---|---|
cites | cdi_FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783 |
container_end_page | 910 |
container_issue | 4 |
container_start_page | 906 |
container_title | British journal of cancer |
container_volume | 90 |
creator | Ching, L-M Zwain, S Baguley, B C |
description | 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is currently undergoing clinical evaluation as an antivascular agent for the treatment of cancer. We have previously demonstrated that DMXAA induces apoptosis of vascular endothelial cells in murine tumour sections and in a breast carcinoma biopsy from one patient in a Phase I trial. We wished to determine the tissue selectivity of this effect and its relationship to induced blood flow changes. Mice with Colon 38 tumours were treated with DMXAA and tissues were examined for apoptosis by TdT-mediated dUTP nick-end labelling (TUNEL). Hoechst 33342 was used to stain functional vessels, with the loss of stained vessels used as a measure of tumour vascular collapse. Treatment with DMXAA at 25 mg kg
−1
, its maximum tolerated dose (MTD), showed, after 3 h, a 12-fold increase in TUNEL staining of tumour vascular endothelial cells. In contrast, tissue from the heart, brain, liver and spleen showed no increase. Induction of apoptosis in tumour tissue was both dose-dependent, observable at doses as low as 5 mg kg
−1
, and time-dependent. Apoptosis was significantly lower in Colon 38 tumours of mice, with a targeted disruption in the TNF gene (TNF
−/−
), or in the TNF receptor 1 gene (TNFR
−/−
), as compared with that in wild-type mice. Increasing the DMXAA dose to 50 mg kg
−1
in these knockout mice raised tumour apoptosis to a level comparable to that induced in wild-type mice given DMXAA at the MTD. For all the data, a significant correlation (
r
=0.94;
P |
doi_str_mv | 10.1038/sj.bjc.6601606 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2410181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>984037121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783</originalsourceid><addsrcrecordid>eNp1kU2LFDEQhoMo7rh69ShBWG89m_RX0hdhWD9hRRAFbyGdTk-nSSdjkt7B3-EftpppHRXMJam8T1Uq9SL0lJItJQW_juO2HdW2rgmtSX0PbWhV5BnlObuPNoQQlpEmJxfoUYwjhA3h7CG6oGXD4JRv0I9P2spkvIuDOeBWp6PWDqd58nPA2nU-DdoaabHS1mJ58Ifko4lYuu4X1VrvO9xbf8RxmFPnjw733kJs3B6noGWatEv4aNKAoRzkJnMno5qtDFjuF-3Vh6-7HTYOT0bpx-hBL23UT9b9En158_rzzbvs9uPb9ze720wVDa-zvK2UZlXVV1p3VLaqpHUuS9lQDkpeFrBKxXhbtkQVvGFNTztOtSIdW-6LS_TyVPcwt5PuFDQSpBWHYCYZvgsvjfhbcWYQe38n8pISyikUeLEWCP7brGMSk4nLoKTTfo6Cgykl5QzA5_-AI0zOwedEXoAtpKoWaHuCVPAxBt3_7oQSsZgt4ijAbLGaDQnP_uz_jK_uAnC1AjBtafsgnTLxzFV10bCyAe76xEWQ3F6Hc3v_efonwN3G-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230000557</pqid></control><display><type>article</type><title>Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice</title><source>PubMed Central</source><creator>Ching, L-M ; Zwain, S ; Baguley, B C</creator><creatorcontrib>Ching, L-M ; Zwain, S ; Baguley, B C</creatorcontrib><description>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is currently undergoing clinical evaluation as an antivascular agent for the treatment of cancer. We have previously demonstrated that DMXAA induces apoptosis of vascular endothelial cells in murine tumour sections and in a breast carcinoma biopsy from one patient in a Phase I trial. We wished to determine the tissue selectivity of this effect and its relationship to induced blood flow changes. Mice with Colon 38 tumours were treated with DMXAA and tissues were examined for apoptosis by TdT-mediated dUTP nick-end labelling (TUNEL). Hoechst 33342 was used to stain functional vessels, with the loss of stained vessels used as a measure of tumour vascular collapse. Treatment with DMXAA at 25 mg kg
−1
, its maximum tolerated dose (MTD), showed, after 3 h, a 12-fold increase in TUNEL staining of tumour vascular endothelial cells. In contrast, tissue from the heart, brain, liver and spleen showed no increase. Induction of apoptosis in tumour tissue was both dose-dependent, observable at doses as low as 5 mg kg
−1
, and time-dependent. Apoptosis was significantly lower in Colon 38 tumours of mice, with a targeted disruption in the TNF gene (TNF
−/−
), or in the TNF receptor 1 gene (TNFR
−/−
), as compared with that in wild-type mice. Increasing the DMXAA dose to 50 mg kg
−1
in these knockout mice raised tumour apoptosis to a level comparable to that induced in wild-type mice given DMXAA at the MTD. For all the data, a significant correlation (
r
=0.94;
P
<0.001) was found between logarithmic percentage apoptosis induction and the logarithmic density of Hoechst-stained vessels. These results suggest that blood flow inhibition caused by DMXAA is tumour tissue-specific and is a consequence of induction of apoptosis in tumour vascular endothelial cells.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6601606</identifier><identifier>PMID: 14970872</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Apoptosis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chemotherapy ; Colonic Neoplasms - blood supply ; Colonic Neoplasms - pathology ; Colonic Neoplasms - veterinary ; Drug Resistance ; Endothelial Cells - physiology ; Endothelium ; Epidemiology ; Experimental Therapeutics ; In Situ Nick-End Labeling ; Labeling ; Medical research ; Medical sciences ; Mice ; Mice, Knockout ; Molecular Medicine ; Neoplasms, Experimental ; Oncology ; Pharmacology. Drug treatments ; Regional Blood Flow ; Tumor Necrosis Factor-alpha - biosynthesis ; Tumor Necrosis Factor-alpha - pharmacology ; Tumor necrosis factor-TNF ; Tumors ; Xanthones - pharmacology</subject><ispartof>British journal of cancer, 2004-02, Vol.90 (4), p.906-910</ispartof><rights>The Author(s) 2004</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Feb 23, 2004</rights><rights>Copyright © 2004 Cancer Research UK 2004 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783</citedby><cites>FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410181/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410181/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15639749$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14970872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ching, L-M</creatorcontrib><creatorcontrib>Zwain, S</creatorcontrib><creatorcontrib>Baguley, B C</creatorcontrib><title>Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is currently undergoing clinical evaluation as an antivascular agent for the treatment of cancer. We have previously demonstrated that DMXAA induces apoptosis of vascular endothelial cells in murine tumour sections and in a breast carcinoma biopsy from one patient in a Phase I trial. We wished to determine the tissue selectivity of this effect and its relationship to induced blood flow changes. Mice with Colon 38 tumours were treated with DMXAA and tissues were examined for apoptosis by TdT-mediated dUTP nick-end labelling (TUNEL). Hoechst 33342 was used to stain functional vessels, with the loss of stained vessels used as a measure of tumour vascular collapse. Treatment with DMXAA at 25 mg kg
−1
, its maximum tolerated dose (MTD), showed, after 3 h, a 12-fold increase in TUNEL staining of tumour vascular endothelial cells. In contrast, tissue from the heart, brain, liver and spleen showed no increase. Induction of apoptosis in tumour tissue was both dose-dependent, observable at doses as low as 5 mg kg
−1
, and time-dependent. Apoptosis was significantly lower in Colon 38 tumours of mice, with a targeted disruption in the TNF gene (TNF
−/−
), or in the TNF receptor 1 gene (TNFR
−/−
), as compared with that in wild-type mice. Increasing the DMXAA dose to 50 mg kg
−1
in these knockout mice raised tumour apoptosis to a level comparable to that induced in wild-type mice given DMXAA at the MTD. For all the data, a significant correlation (
r
=0.94;
P
<0.001) was found between logarithmic percentage apoptosis induction and the logarithmic density of Hoechst-stained vessels. These results suggest that blood flow inhibition caused by DMXAA is tumour tissue-specific and is a consequence of induction of apoptosis in tumour vascular endothelial cells.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Colonic Neoplasms - blood supply</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - veterinary</subject><subject>Drug Resistance</subject><subject>Endothelial Cells - physiology</subject><subject>Endothelium</subject><subject>Epidemiology</subject><subject>Experimental Therapeutics</subject><subject>In Situ Nick-End Labeling</subject><subject>Labeling</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Molecular Medicine</subject><subject>Neoplasms, Experimental</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Regional Blood Flow</subject><subject>Tumor Necrosis Factor-alpha - biosynthesis</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><subject>Xanthones - pharmacology</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp1kU2LFDEQhoMo7rh69ShBWG89m_RX0hdhWD9hRRAFbyGdTk-nSSdjkt7B3-EftpppHRXMJam8T1Uq9SL0lJItJQW_juO2HdW2rgmtSX0PbWhV5BnlObuPNoQQlpEmJxfoUYwjhA3h7CG6oGXD4JRv0I9P2spkvIuDOeBWp6PWDqd58nPA2nU-DdoaabHS1mJ58Ifko4lYuu4X1VrvO9xbf8RxmFPnjw733kJs3B6noGWatEv4aNKAoRzkJnMno5qtDFjuF-3Vh6-7HTYOT0bpx-hBL23UT9b9En158_rzzbvs9uPb9ze720wVDa-zvK2UZlXVV1p3VLaqpHUuS9lQDkpeFrBKxXhbtkQVvGFNTztOtSIdW-6LS_TyVPcwt5PuFDQSpBWHYCYZvgsvjfhbcWYQe38n8pISyikUeLEWCP7brGMSk4nLoKTTfo6Cgykl5QzA5_-AI0zOwedEXoAtpKoWaHuCVPAxBt3_7oQSsZgt4ijAbLGaDQnP_uz_jK_uAnC1AjBtafsgnTLxzFV10bCyAe76xEWQ3F6Hc3v_efonwN3G-Q</recordid><startdate>20040223</startdate><enddate>20040223</enddate><creator>Ching, L-M</creator><creator>Zwain, S</creator><creator>Baguley, B C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20040223</creationdate><title>Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice</title><author>Ching, L-M ; Zwain, S ; Baguley, B C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Colonic Neoplasms - blood supply</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - veterinary</topic><topic>Drug Resistance</topic><topic>Endothelial Cells - physiology</topic><topic>Endothelium</topic><topic>Epidemiology</topic><topic>Experimental Therapeutics</topic><topic>In Situ Nick-End Labeling</topic><topic>Labeling</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Molecular Medicine</topic><topic>Neoplasms, Experimental</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Regional Blood Flow</topic><topic>Tumor Necrosis Factor-alpha - biosynthesis</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><topic>Xanthones - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ching, L-M</creatorcontrib><creatorcontrib>Zwain, S</creatorcontrib><creatorcontrib>Baguley, B C</creatorcontrib><collection>SpringerOpen</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ching, L-M</au><au>Zwain, S</au><au>Baguley, B C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2004-02-23</date><risdate>2004</risdate><volume>90</volume><issue>4</issue><spage>906</spage><epage>910</epage><pages>906-910</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is currently undergoing clinical evaluation as an antivascular agent for the treatment of cancer. We have previously demonstrated that DMXAA induces apoptosis of vascular endothelial cells in murine tumour sections and in a breast carcinoma biopsy from one patient in a Phase I trial. We wished to determine the tissue selectivity of this effect and its relationship to induced blood flow changes. Mice with Colon 38 tumours were treated with DMXAA and tissues were examined for apoptosis by TdT-mediated dUTP nick-end labelling (TUNEL). Hoechst 33342 was used to stain functional vessels, with the loss of stained vessels used as a measure of tumour vascular collapse. Treatment with DMXAA at 25 mg kg
−1
, its maximum tolerated dose (MTD), showed, after 3 h, a 12-fold increase in TUNEL staining of tumour vascular endothelial cells. In contrast, tissue from the heart, brain, liver and spleen showed no increase. Induction of apoptosis in tumour tissue was both dose-dependent, observable at doses as low as 5 mg kg
−1
, and time-dependent. Apoptosis was significantly lower in Colon 38 tumours of mice, with a targeted disruption in the TNF gene (TNF
−/−
), or in the TNF receptor 1 gene (TNFR
−/−
), as compared with that in wild-type mice. Increasing the DMXAA dose to 50 mg kg
−1
in these knockout mice raised tumour apoptosis to a level comparable to that induced in wild-type mice given DMXAA at the MTD. For all the data, a significant correlation (
r
=0.94;
P
<0.001) was found between logarithmic percentage apoptosis induction and the logarithmic density of Hoechst-stained vessels. These results suggest that blood flow inhibition caused by DMXAA is tumour tissue-specific and is a consequence of induction of apoptosis in tumour vascular endothelial cells.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>14970872</pmid><doi>10.1038/sj.bjc.6601606</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 2004-02, Vol.90 (4), p.906-910 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2410181 |
source | PubMed Central |
subjects | Animals Antineoplastic agents Antineoplastic Agents - pharmacology Apoptosis Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Chemotherapy Colonic Neoplasms - blood supply Colonic Neoplasms - pathology Colonic Neoplasms - veterinary Drug Resistance Endothelial Cells - physiology Endothelium Epidemiology Experimental Therapeutics In Situ Nick-End Labeling Labeling Medical research Medical sciences Mice Mice, Knockout Molecular Medicine Neoplasms, Experimental Oncology Pharmacology. Drug treatments Regional Blood Flow Tumor Necrosis Factor-alpha - biosynthesis Tumor Necrosis Factor-alpha - pharmacology Tumor necrosis factor-TNF Tumors Xanthones - pharmacology |
title | Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A24%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20tumour%20endothelial%20cell%20apoptosis%20and%20tumour%20blood%20flow%20shutdown%20following%20treatment%20with%20the%20antivascular%20agent%20DMXAA%20in%20mice&rft.jtitle=British%20journal%20of%20cancer&rft.au=Ching,%20L-M&rft.date=2004-02-23&rft.volume=90&rft.issue=4&rft.spage=906&rft.epage=910&rft.pages=906-910&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6601606&rft_dat=%3Cproquest_pubme%3E984037121%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3986-2b5ce755f5eed1abc4162a4a918b5c2433334c78b4b0c38979f1d81ec0d74c783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230000557&rft_id=info:pmid/14970872&rfr_iscdi=true |